Clin2
NCT05511909Possibly a fitRecruiting

Buspirone study for opioid withdrawal symptoms

Opioid Use DisorderOpioid WithdrawalOpioid CravingAnxiety

Treatments studied

Part of Mental health clinical trials.

This Phase 2 study tests whether buspirone can help reduce symptoms during opioid detox (withdrawal). You may be able to take part if you have opioid withdrawal and are planning medically supervised detox.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • Be between 18 and 75 years old
  • Have a urine test that shows opioids
  • Have moderate to severe opioid use disorder and show signs your body is physically dependent
  • Be interested in starting opioid detox (stopping opioids under care)
  • Not be pregnant or breastfeeding
  • Not currently be in methadone or buprenorphine maintenance treatment

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05027919Recruiting· Phase 2
Testing ways to predict opioid withdrawal during a taper

This Phase 2 study looks at what opioid withdrawal looks like in the body and whether they can measure it in a meaningful way. You may join if you have an opioid use disorder, can show physical dependence, and are interested in tapering (gradually reducing) opioids under study care.

Baltimore, Maryland
NCT07128524Recruiting· Phase 2
Ketones for opioid craving study

This trial tests if a ketone supplement can help reduce cravings during opioid withdrawal treatment. Participants take the supplement daily and are monitored for changes in craving and withdrawal symptoms.

Wernersville, Pennsylvania
NCT07094672Not yet recruiting
Opioid withdrawal symptom study

This study aims to better understand how people experience opioid withdrawal. You will be asked to describe your symptoms, which may help develop a new tool to measure withdrawal more accurately.

Baltimore, Maryland
NCT05829655Recruiting· Early Phase 1
Measuring drug cravings in people with opioid use disorder

This study tests whether the medication suvorexant can reduce drug cravings in people with opioid use disorder. You will take either suvorexant or a placebo and have your cravings measured in a safe setting.

Baltimore, Maryland
NCT06067737Recruiting· Phase 2
Psilocybin and buprenorphine for opioid use disorder

This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.

Baltimore, Maryland
NCT06786325Recruiting· Phase 2
Psilocybin treatment study for opioid use disorder

This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.

Philadelphia, Pennsylvania

Hear when a new Opioid Use Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.